- A head-to-head trial showed Eli Lilly's obesity drug, Zepbound (tirzepatide), resulted in significantly greater weight loss than Novo Nordisk's Wegovy (semaglutide).
- Participants on Zepbound lost an average of 50 pounds (22.8 kg) over 72 weeks, compared to 33 pounds (15 kg) for those on Wegovy.
- Zepbound targets two appetite-regulating hormones, while Wegovy targets only one.
- Both drugs showed improvements in health markers like blood pressure and blood sugar levels, but Zepbound had a higher rate of achieving significant weight loss (at least 25 per cent of body weight).
- While most side effects were mild to moderate gastrointestinal issues, access and affordability remain a concern for both drugs.
IN FULL
First head-to-head trial of obesity drugs reveals best jab for weight loss
